Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Prices $400M Common Stock Offering

NEW YORK – Invitae said after the close of the market on Thursday that it has priced an underwritten public offering of 7,766,990 shares of its common stock at $51.50 per share.

The molecular diagnostics firm expects gross proceeds of approximately $400 million from the offering, which it announced on Wednesday. Invitae has also granted underwriters a 30-day option to purchase an additional 1,165,048 shares of its common stock at the public offering price.

The company plans to use the net proceeds for working capital and corporate expenses, to improve its platform and oncology and reproductive assays, as well as to expand internationally and acquire assets.  The offering is expected to close on or about Jan. 26.

JP Morgan Securities, Morgan Stanley, Cowen and Company, and SVB Leerink are acting as book-running managers, and William Blair & Company is acting as co-manager for the offering.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.